What Do Outcomes Teach Us About Screening Criteria?

Every angel group eventually wonders whether its screening criteria are helping or hurting. When a company you passed on lands a big acquisition or files for an IPO, the quiet question surfaces: Did we miss something? Over time, those moments create pressure to loosen standards – especially in life sciences, where compelling science and strong narratives can push deals beyond what angel capital is designed to support.

To address that question head-on, Mid-Atlantic Bio Angels (BioAngels) conducted a retrospective analysis of its life science application and outcome data from 2012 to 2023, covering 1,094 companies across therapeutics, devices, diagnostics, and digital health. The group invested in roughly one percent of applicants. This article – published by the Angel Capital Association – examines what the outcomes reveal about whether disciplined screening improves angel investing results, or simply filters out winners.

Key Takeaways

• Screening materially shifts outcome distributions. Funded companies were far more likely to remain active and far less likely to fail or stall than those declined – 83% of funded companies remain active, compared to 38% of unfunded ones.
• Exit labels alone overstate success. Counting acquisitions or IPOs without accounting for return multiples, dilution, and timing paints a misleading picture. Most exits clustered in low-return categories even when the headline looked positive.
• High-quality misses were rare. Of the 1,074 companies BioAngels declined, only four produced outcomes that would qualify as strong angel-level exits. Many that appeared successful in hindsight required too much capital, too much time, or too little early-investor ownership to actually deliver.
• Acquisitions – not IPOs – drove meaningful returns. BioAngels’ best exits came from acquisitions at the right inflection point, before extended timelines and heavy follow-on financing eroded early ownership. IPOs, while notable, rarely translated into strong angel-level outcomes.
• Screening works by protecting ownership durability. Capital intensity and dilution quietly destroy value over time. Criteria that screen for angel-friendly capital requirements and plausible acquisition paths help guard against those slow erosions.

The Organizing Framework

BioAngels’ screening is built around a simple but disciplined set of questions: When is the most likely exit? How much capital is needed to get there? Who is the likely buyer? How much ownership will early investors retain? These questions are applied consistently across sub-sectors, even as the specifics differ between a therapeutics company targeting Phase 2 acquisition and a device company seeking clearance before becoming an M&A target.

The analysis assessed four interrelated risk dimensions – technology and development, market and commercial feasibility, management and execution, and financial and capital strategy – all viewed through an acquisition lens rather than a standalone-growth lens. The goal was not to predict winners, but to avoid predictable mistakes: capital mismatches, dilution traps, and paths that extend timelines until early investors are left with little meaningful ownership.

Why This Analysis Matters

Without tracking how companies that did not receive investment perform over time, even a small number of visible misses can create the illusion that discipline costs returns. This retrospective exercise was a direct attempt to address that blind spot. The data found little evidence that BioAngels’ criteria meaningfully filtered out true angel-scale winners – and strong evidence that they increased the odds of funding companies that survived and, in rare but critical cases, delivered the returns that make angel investing worthwhile.

Read the full article here: What Do Outcomes Teach Us About Screening Criteria?